The future of drug safety testing: expanding the view and narrowing the focus

Drug Discovery Today

Volumn 14, Issue 3-4, 2009, Pages 162-167

  Stevens, James L ^a   Baker, Thomas K ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTOXICITY; CYTOTOXICITY; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG SAFETY; LIVER INJURY; LIVER TOXICITY; NEUROTOXICITY; REVIEW; RISK ASSESSMENT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL; TOXICITY TESTS;

EID: 58849132807     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.11.009     Document Type: Review

References (42)

1. Committee on the Assessment of the US Drug Safety System, et al. The Future of Drug Safety: Promoting and Protecting the Health of the Public (2007), National Academy Press
2. Olson H., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32 (2000) 56-67
3. Stevens J.L. Future of toxicology - mechanisms of toxicity and drug safety: where do we go from here?. Chem. Res. Toxicol. 19 (2006) 1393-1401
4. Schmid E.F., and Smith D.A. Is pharmaceutical R&D just a game of chance or can strategy make a difference?. Drug Discov. Today 9 (2004) 18-26
5. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 21 (2008) 84-92
6. Pirmohamed M., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329 (2004) 15-19
7. Alden C.L., and Lin J.S.P. Predictive toxicology technology for avoiding idiosyncratic liver injury. Preclinica (2003) 27-35 May/June
8. Shah R.R. Can pharmacogenetics help rescue drugs withdrawn from the market?. Pharmacogenomics 7 (2006) 889-908
9. Fung M., et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1999. Drug Inform. J. 35 (2001) 293-317
10. Lasser K.E., et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 287 (2002) 2215-2220
11. CDER Report to the Nation: Improving Public Health through Human Drugs. http://www.fda.gov/CDER/about/default.html
12. Wilke R.A., et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6 (2007) 904-916
13. Kramer J.A., et al. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discov. 6 (2007) 636-649
14. Estimating Maximum Safe Starting does in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Center for Drug Evaluation and Research http://www.fda.gov/cder/Guidance/5541fnl.html. 2005
15. Guengerich F.P., and MacDonald J.S. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol. 20 (2007) 344-369
16. Eisenbrand G., et al. Methods of in vitro toxicology. Food Chem. Toxicol. 40 (2002) 193-236
17. Evans S.M., et al. Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential. Toxicol. In Vitro 15 (2001) 579-584
18. Johnson T.E., et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol. Appl. Pharmacol. 200 (2004) 237-250
19. Gough A.H., and Johnston P.A. Requirements, features, and performance of high content screening platforms. Methods Mol. Biol. 356 (2007) 41-61
20. Ekins S., et al. Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol. Sci. 26 (2005) 202-209
21. Segalat L. Invertebrate animal models of diseases as screening tools in drug discovery. ACS Chem. Biol. 2 (2007) 231-236
22. Rubinstein A.L. Zebrafish assays for drug toxicity screening. Expert. Opin. Drug Metab. Toxicol. 2 (2006) 231-240
23. Zon L.I., and Peterson R.T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4 (2005) 35-44
24. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Center for Drug Evaluation and Research http://www.fda.gov/cder/guidance/7507dft.html. 2007
25. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol. Drug Saf. 15 (2006) 241-243
26. Graham D.J., et al. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am. J. Gastroenterol. 98 (2003) 175-179
27. Center for Drug Evaluation and Review. The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. http://www.fda.gov/cber/gdlns/ichqt.html. 2005
28. Sasseville V.G., et al. Testing paradigm for prediction of development-limiting barriers and human drug toxicity. Chem. Biol. Interact. 150 (2004) 9-25
29. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur. J. Heart Fail. 6 (2004) 257-260
30. Maisel A.S., et al. Cardiac biomarkers: a contemporary status report. Nat. Clin. Pract. Cardiovasc. Med. 3 (2006) 24-34
31. Hazell L., and Shakir S.A. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 29 (2006) 385-396
32. Hauben M., and Reich L. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation. J. Clin. Pharmacol. 45 (2005) 378-384
33. Moore T.J., et al. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch. Intern. Med. 167 (2007) 1752-1759
34. Weinshilboum R., and Wang L. Pharmacogenomics: bench to bedside. Nat. Rev. Drug Discov. 3 (2004) 739-748
35. Weinshilboum R.M., and Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu. Rev. Genomics Hum. Genet. 7 (2006) 223-245
36. Giacomini K.M., et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin. Pharmacol. Ther. 81 (2007) 328-345
37. Fox J., et al. The clinical implications of antiretroviral pharmacogenomics. Pharmacogenomics 7 (2006) 587-596
38. Guo Y., et al. In silico pharmacogenetics of warfarin metabolism. Nat. Biotechnol. 24 (2006) 531-536
39. Wu A.H., et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9 (2008) 169-178
40. Gatti D., et al. Genome-level analysis of genetic regulation of liver gene expression networks. Hepatology 46 (2007) 548-557
41. Bogue M.A., et al. Mouse Phenome Database (MPD). Nucleic Acids Res. 35 (2007) D643-D649
42. Mayne J.T., et al. Informed toxicity assessment in drug discovery: systems-based toxicology. Curr. Opin. Drug Discov. Dev. 9 (2006) 75-83